Famitinib - CAS 945380-27-8
Catalog number: 945380-27-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment.  Famitinib is a structural analogue ofsunitinib, is a novel and potent multi-targeted RTK inhibitor that is currently undergoing phase II clinical trials in China for the treatment of renal cell carcinoma, gastrointestinal stromal tumours, pancreatic cancer, and nasopharyngeal carcinoma. Compared with sunitinib, famitinib exhibits superior inhibition activities against multiple RTKs.
Famitinib; SHR1020; SHR 1020; SHR-1020
Canonical SMILES:
Current Developer:
Jiangsu Hengrui Medicine Co. Ltd. China
1.Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.
Mu X1,2, Ma J1, Zhang Z1, Zhou H1, Xu S1, Qin Y1, Huang J1, Yang K1, Wu G1. Int J Radiat Biol. 2015;91(9):771-6. doi: 10.3109/09553002.2015.1062574. Epub 2015 Sep 21.
PURPOSE: Famitinib is a novel tyrosine kinase inhibitor. We investigated the effects of famitinib on the radiosensitivity of human nasopharyngeal carcinoma (NPC) cell radiosensitivity in vitro and in vivo, and explored its possible mechanisms.
2.Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Cao J1, Zhang J, Wang Z, Wang B, Lv F, Wang L, Hu X. Cancer Chemother Pharmacol. 2014 Aug;74(2):389-98. doi: 10.1007/s00280-014-2505-x. Epub 2014 Jun 18.
PURPOSE: Hypothyroidism is a common adverse event in patients treated with anti-VEGFR-2 targeting agents and may be a valuable predictive factor of efficacy. Famitinib is an inhibitor of multiple tyrosine kinases mainly targeting VEGFR-2. The objectives of this study were to assess the efficacy and safety of famitinib in patients with pretreated HER2-negative metastatic breast cancer (MBC) and to explore potential of famitinib-induced hypothyroidism and serum vascular endothelial growth factor (VEGF) level for efficacy prediction.
3.[Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model].
Yu MM, Gao ZW, Chen XY, Zhong DF. Yao Xue Xue Bao. 2014 Dec;49(12):1684-8.
This study is to establish physiologically based pharmacokinetic (PBPK) models of famitinib in rat and monkey, and then to predict the pharmacokinetics and tissue distribution of famitinib in human based on the PBPK models. According to published paper, previous studies and the chemical properties of famitinib predicted by ACD/ADME suite and SimCYP, the PBPK models of rat and monkey were established and optimized using GastroPlus. And then, the PBPK models were applied to predict the pharmacokinetic and tissue distribution of famitinib in human. The results showed that the PBPK models of rat and monkey can fit the observed data well, and the AUC0-∞, ratios of observed and calculated data in rat and monkey were 1.00 and 0.97, respectively. The AUC0-∞, ratios of observed and predicted data in human were 1.63 (rat to human) and 1.57 (monkey to human), respectively. The rat and monkey PBPK models of famitinib were well established, and the PBPK models were applied in predicting pharmacokinetic of famitinib in human successfully.
4.Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.
Xie C1, Zhou J, Guo Z, Diao X, Gao Z, Zhong D, Jiang H, Zhang L, Chen X. Br J Pharmacol. 2013 Apr;168(7):1687-706. doi: 10.1111/bph.12047.
BACKGROUND AND PURPOSE: Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment. This study aims to characterize the metabolic and bioactivation pathways of famitinib.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 193000-39-4 ZM323881 hydrochloride

ZM323881 hydrochloride
(CAS: 193000-39-4)

Potent and selective inhibitor of VEGFR2 (IC50: 2 nM for VEGFR2 vs >50 mM for VEGFR1 respectively)

CAS 73771-04-7 Prednicarbate

(CAS: 73771-04-7)

Prednicarbate is a glucocorticoid receptor agonist. It is a synthetic non-halogenated double-ester derivative of the corticosteroid prednisolone with anti-infla...

CAS 300801-52-9 TG003

(CAS: 300801-52-9)

TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibito...

CAS 107-41-5 2-Methyl-2,4-pentanediol

(CAS: 107-41-5)

2-Methyl-2,4-pentanediol, an analog of hexylene glycol, is a small molecular surfactant which could be useful as an environmentally friendly industrial coating ...

CAS 1443437-74-8 CCG 203971

CCG 203971
(CAS: 1443437-74-8)

CCG 203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM). CCG 203971 inhibits fibrosis by targeting the MRTF/SRF gene ...

CAS 181936-98-1 KC 12291 hydrochloride

KC 12291 hydrochloride
(CAS: 181936-98-1)

KC 12291 hydrochloride is the hydrochloride salt of KC 12291, which is an orally active atypical inhibitor of voltage-gated sodium channels in ischemia. It inhi...

CAS 26305-03-3 Pepstatin A

Pepstatin A
(CAS: 26305-03-3)

Pepstatin A is a potent aspartic protease inhibitor, and also inhibits HIV replication.It is a hexa-peptide containing the unusual amino acid statine (Sta, (3S,...

FY26 (complex)
(CAS: 1255143-82-8)

This active moleculr is a Os(II) anticancer drug candidate. It can generate reactive oxygen species and disrupt the redox balance in cancer cells. Using FY26 an...

Chemical Structure

CAS 945380-27-8 Famitinib

Quick Inquiry

Verification code

Featured Items